Fulcrum Therapeutics (FULC)

• Market cap: $722M
• 1 day: -1.92%
• 5 days: 0.66%
• 1 month: -5.38%
• 3 months: 24.77%
• 6 months: 55.51%
• Year to date: -1.74%
• 1 year: 156.7%
• 5 years: -2.28%
• 10 years: -20.52%
• Sector: Healthcare
• Industry: Biotechnology

About: Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.

Employees: 45